Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
About this item
Full title
Author / Creator
Heuser, Michael , Palmisiano, Neil , Mantzaris, Ioannis , Mims, Alice , DiNardo, Courtney , Silverman, Lewis R. , Wang, Eunice S. , Fiedler, Walter , Baldus, Claudia , Schwind, Sebastian , Pardee, Timothy , Perl, Alexander E. , Cai, Charles , Kaulfuss, Stefan , Lagkadinou, Eleni , Rentzsch, Christine , Wagner, Markus , Wilkinson, Gary , Wu, Bingyan , Jeffers, Michael , Genvresse, Isabelle and Krämer, Alwin
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses ranging from 300 to 1500 mg twice-daily. BAY1436032 exhibited a relatively short half-life and apparent...
Alternative Titles
Full title
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Authors, Artists and Contributors
Author / Creator
Palmisiano, Neil
Mantzaris, Ioannis
Mims, Alice
DiNardo, Courtney
Silverman, Lewis R.
Wang, Eunice S.
Fiedler, Walter
Baldus, Claudia
Schwind, Sebastian
Pardee, Timothy
Perl, Alexander E.
Cai, Charles
Kaulfuss, Stefan
Lagkadinou, Eleni
Rentzsch, Christine
Wagner, Markus
Wilkinson, Gary
Wu, Bingyan
Jeffers, Michael
Genvresse, Isabelle
Krämer, Alwin
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7584476
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7584476
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/s41375-020-0996-5
